Hormonal
GLP-1 receptor agonists (e.g., Liraglutide) and SGLT2 inhibitors (e.g., Empagliflozin) reduce cardiovascular mortality in Type 2 Diabetes patients, primarily through mechanisms involving insulin sensitivity and weight loss rather than direct glucose lowering.
If you have Type 2 Diabetes and are at high risk for heart problems, medications like Liraglutide (a GLP-1 agonist) or Empagliflozin (an SGLT2 inhibitor) can significantly reduce your risk of dying from cardiovascular causes. These drugs work not just by lowering blood sugar, but by improving how your body uses insulin and promoting weight loss. Discuss these options with your doctor, especially if you have existing heart disease.
Recent clinical trials about the cardiovascular safety of empagliflozin and liraglutide demonstrated a convincing lowering effect on mortality from cardiovascular causes among the patients with type 2 diabetes. ... It is important to note that the glucose-lowering effect was moderate, although a feature seen in both empagliflozin and liraglutide was their ability to increase insulin sensitivity.
Why this rating
Based on large, landmark randomized clinical trials (LEADER, EMPA-REG OUTCOME).
Source
Decrease of cardiovascular risk in patients with type 2 diabetes: review of the common strategies and clinical studies
В. В. Салухов et al. · Diabetes Mellitus · 2018
DOI 10.14341/dm9570
More from this paper
- Thiazolidinediones (specifically Pioglitazone) significantly reduce cardiovascular events (stroke, MI, mortality) in patients with Type 2 Diabetes and macroangiopathies or recent stroke/TIA, independent of glucose lowering.Strong
- Reducing insulin resistance, rather than strictly lowering blood glucose, is the primary mechanism for reducing cardiovascular risk in type 2 diabetes.Good
- Intensive lifestyle modification (diet and exercise) reduces cardiovascular risk in Type 2 Diabetes patients, but long-term maintenance of weight loss is difficult, and significant risk reduction is only seen in those who maintain >10% weight loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →